Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer

Table 2 Association between vascular endothelial growth factor-A expression and clinicopathological characteristics n (%)

	n	Tumor VEGF positive cases	Stromal VEGF positive cases
TNM stage
0	9	1 (11.1)	7 (77.8)
I	16	2 (12.5)	6 (37.5)
II	55	32 (58.2)	33 (60.0)
III	66	38 (57.6)	22 (33.3)
IV	19	16 (84.2)	5 (26.3)
Total	165	89 (53.9)	73 (44.2)
		P < 0.0001	P = 0.004
T factor
Tis	9	1 (11.1)	7 (77.8)
T1	7	0 (0.0)	6 (85.7)
T2	25	9 (36.0)	11 (44.0)
T3	111	70 (63.1)	45 (40.5)
T4	13	9 (69.2)	4 (30.8)
Total	165	89 (53.9)	73 (44.2)
		P = 0.0002	P = 0.01
Histological differentiation
Well	47	15 (31.9)	23 (48.9)
Moderate	95	63 (66.3)	41 (43.2)
Poor	8	3 (37.5)	4 (50.0)
Mucinous	10	5 (50.0)	2 (20.0)
Other	5	1 (20.0)	3 (60.0)
		NS	NS
Venous invasion
v0	46	14 (30.4)	27 (58.7)
v1	73	43 (58.9)	29 (39.7)
v2	32	23 (71.9)	15 (46.9)
v3	14	9 (64.3)	2 (14.3)
		P = 0.001	P = 0.015
Lymphatic invasion
ly0	53	16 (30.1)	26 (49.1)
ly1	79	48 (60.8)	39 (49.4)
ly2	28	20 (71.4)	7 (25.0)
ly3	5	5 (100.0)	1 (20.0)
		P < 0.0001	P = 0.04

NS: Not significant; VEGF: Vascular endothelial growth factor.